VERVE-102 for High Cholesterol

(HEART-3 Trial)

Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Verve Therapeutics, Inc.
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.

Who Is on the Research Team?

C1

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

This trial is for adults who have, or are at high risk for, heart and blood vessel diseases like high cholesterol, plaque buildup in arteries (atherosclerosis), heart attack, stroke, or coronary artery disease.

Inclusion Criteria

I have or am at high risk for atherosclerotic cardiovascular disease.

Exclusion Criteria

I have chronic liver disease.
I have been diagnosed with homozygous familial hypercholesterolemia.
I am currently taking or recently took a PCSK9 inhibitor medication.

What Are the Treatments Tested in This Trial?

Interventions

  • VERVE-102

Trial Overview

The study compares a new drug called VERVE-102 to a placebo. Researchers want to see if VERVE-102 can lower bad cholesterol (LDL-C) in people with or at risk of cardiovascular problems.

How Is the Trial Designed?

4

Treatment groups

Experimental Treatment

Placebo Group

Group I: VERVE-102 Dose 3Experimental Treatment1 Intervention
Group II: VERVE-102 Dose 2Experimental Treatment1 Intervention
Group III: VERVE-102 Dose 1Experimental Treatment1 Intervention
Group IV: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Verve Therapeutics, Inc.

Lead Sponsor

Trials
4
Recruited
230+